Navigation Links
VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
Date:3/20/2008

- Top Line Data Is Expected to Be Presented in Third Quarter -

SAN FRANCISCO, March 20 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it has completed patient enrollment in its carotid endarterectomy (CEA) study, the first of three Phase 2 trials investigating VIA-2291, the company's lead product candidate.

VIA-2291 is a potent small molecule drug that targets inflammation in the blood vessel wall, a primary disease process in atherosclerosis. It is being developed as a once-daily, oral drug to potentially decrease the risk of major adverse cardiac events associated with inflammation, including heart attack and stroke.

The CEA study enrolled 50 patients and is designed to provide direct evaluation of VIA-2291's effect on inflammation by analyzing plaque removed from the carotid arteries of patients treated with VIA-2291 or placebo. CEA is a surgical procedure to remove plaque from the carotid artery to increase blood flow to the brain in patients with significant blockage in the artery to reduce the risk of stroke. Patients who are diagnosed with carotid artery blockage are treated for three months with either VIA-2291 or placebo and then undergo a CEA procedure. The trial will also measure standard serum biomarkers of inflammation to measure reduction of inflammation in treated patients.

"Following analysis of the CEA study data, we expect to have important data with respect to VIA-2291's role in reducing vascular inflammation, as measured in the carotid plaque tissue," said Rebecca A. Taub, M.D., senior vice president of research and development of VIA Pharmaceuti
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Most osteoporosis patients want a choice in the medication ... by Mission Pharmacal Company. The survey, conducted by ... community, revealed that 74 percent of osteoporosis patients surveyed ... other than a pill or a tablet. ...
(Date:1/15/2014)... 15, 2014 AARP Foundation today announced it has established ... from the severe cold weather that has gripped much of ... those in need; so to support these emergency relief efforts ... $250,000, which could mean up to $500,000 in aid. The ...
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... Healthcare and,Laboratory Corporation of America(R) Holdings (LabCorp(R)) ... agreement to discuss future,possibilities to co-develop new ... diagnostics, metabolic syndrome, oncology and diabetes. Under ... new tests that,could make the biggest impact ...
... of the American Pain Society ... ... sustained pain relief from diabetic neuropathic pain (DNP),compared to placebo-treated patients, according ... (APS) in Tampa, Fla., "This is the first placebo-controlled trial of ...
Cached Medicine Technology:Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 3Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 4New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 2New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 3New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 4
(Date:4/23/2014)... proliferation of endogenous neural precursor cells cannot alone ... From the perspective of neural plasticity, Dr. Yun ... China observed the effects of functional electrical stimulation ... expression of basic fibroblast growth factor and epidermal ... infarct side. The researchers found that functional electrical ...
(Date:4/22/2014)... the New Jersey Institute of Technology (NJIT) today ... the launch of the New Jersey Innovation Institute ... model for business innovation through the leveraging of ... U.S. Senator Cory Booker, Panasonic Corp. of North ... Lieutenant Governor Kim Guadagno, New Jersey Secretary of ...
(Date:4/22/2014)... primary care for low-income patients may ease the ... while improving patient health, researchers have concluded. , ... clinics that avoid costs associated with insurance administration ... admission rates and emergency room visits, according to ... , The researchers estimated that the major ...
(Date:4/22/2014)... risk of pregnancy among women using a newer method ... 10 times greater over a 10-year period than using ... researchers at Yale University and UC Davis has found. ... Contraception , the study found the higher risk ... the brand name Essure. , "This study provides ...
(Date:4/22/2014)... Johns Hopkins scientists have found a way to block ... development of atherosclerosis, the main cause of heart attacks ... humans. The condition develops when fat builds inside blood ... hardened, greatly reducing their ability to feed oxygen-rich blood ... a series of experiments, described April 7 in the ...
Breaking Medicine News(10 mins):Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4
... influenza testing is associated with reductions in the use ... ,The study was posted online today that ... of Archives of Internal Medicine, one of the JAMA/Archives ... speed at which influenza and other viral diseases are ...
... stress and depression,// may be associated with higher ... in turn are related to an increased risk for ... 22 issue of Archives of Internal Medicine, one of ... studies have linked psychosocial characteristics with cardiovascular disease and ...
... Union after a break of six months. Officials from Hungary ... holding of 3000 geese, and the death of 40 geese. The ... has been confirmed as the deadly H5N1 strain, samples are being ... measures are on to control the spread. A protection zone of ...
... Is the everyday talk of HIV/AIDS falling on deaf ears? ‘Careless’ ... today,// who appear to be completely in-charge of their lives, yet ... ,A new survey has shown that, nearly three out of ... getting HIV. , ,The Body Shop and MTV got ...
... history of abuse by intimate partners have significantly higher ... history of such abuse, according to a study conducted ... ,The higher costs and utilization continued long after the ... University of Washington (UW), and the Harborview Injury Prevention ...
... is how some passengers describe it.// , ... who were infected with a stomach flu-causing bug; norovirus aboard ... , This virus causes a contagious gastric illness, gastroenteritis that ... , The liner’s owner Cunard Line notified ...
Cached Medicine News:Health News:Rapid Flu Testing Decreases Antibiotic Use in Hospitalized Adults 2Health News:Psychosocial Factors Associated With Higher Levels of Inflammatory Markers 2Health News:Fowl Fall in Hungary-Bird Flu Strikes 2Health News:Health Care Costs - Significant for Abused Women 2
Codman Hakim Programmable micro offers the ability to optimize the opening pressure of a shunt system before and after implantation. A shunted patient's condition will often change over the course of...
Codman Hakim Programmable valve cylindrical with PrechamberInline offers the ability to optimize the opening pressure of a shunt system before and after implantation. A shunted patient's condition wi...
... V is a low viscosity bone cement, ... vertebroplasty. The bone cement is injected into ... Osteopal V is used for the augmentation ... zirconium dioxide is included in the cement ...
Leadpoint Micro-Electrode Recording...
Medicine Products: